{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:58:46Z","timestamp":1791921526729,"version":"4.3.4"},"reference-count":70,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2020,10,22]],"date-time":"2020-10-22T00:00:00Z","timestamp":1603324800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JoF"],"abstract":"<jats:p>Fosmanogepix is a first-in-class antifungal currently in Phase 2 clinical trials for the treatment of invasive fungal infections caused by Candida, Aspergillus and rare molds. Fosmanogepix is the N-phosphonooxymethylene prodrug of manogepix, an inhibitor of the fungal enzyme Gwt1. Manogepix demonstrates broad spectrum in vitro activity against yeasts and molds, including difficult to treat pathogens. Because of its novel mechanism of action, manogepix retains potency against many resistant strains including echinocandin-resistant Candida and azole-resistant Aspergillus. Manogepix is also active against pathogens that demonstrate intrinsic resistance to other drug classes, such as Scedosporium, Lomentospora prolificans, and Fusarium with variable activity against Mucorales. Fosmanogepix demonstrates significant in vivo efficacy in mouse and rabbit disseminated infection models due to C. albicans, C. glabrata, C. auris, C. tropicalis, Coccidioides immitis, and F. solani as well as pulmonary infection models of A. fumigatus, A. flavus, S.prolificans, S. apiospermum and Rhizopus arrhizus. Clinical trials demonstrated high oral bioavailability (&gt;90%), enabling switching between fosmanogepix intravenous and oral formulations without compromising blood levels. Favorable drug-drug interaction, tolerability, and wide tissue distribution profiles are observed making fosmanogepix an attractive option for the treatment of invasive fungal infections. This systematic review summarizes the findings of published data on fosmanogepix.<\/jats:p>","DOI":"10.3390\/jof6040239","type":"journal-article","created":{"date-parts":[[2020,10,22]],"date-time":"2020-10-22T10:27:58Z","timestamp":1603362478000},"page":"239","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":218,"title":["Fosmanogepix: A Review of the First-in-Class Broad Spectrum Agent for the Treatment of Invasive Fungal Infections"],"prefix":"10.3390","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3060-1328","authenticated-orcid":false,"given":"Karen Joy","family":"Shaw","sequence":"first","affiliation":[{"name":"Hearts Consulting Group, LLC, Poway, CA 92064, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3787-8530","authenticated-orcid":false,"given":"Ashraf S.","family":"Ibrahim","sequence":"additional","affiliation":[{"name":"The Lundquist Institute for Biomedical Innovation at Harbor-University of California Los Angeles (UCLA) Medical Center, Torrance, CA 90502, USA"},{"name":"David Geffen School of Medicine at University of California, Los Angeles (UCLA), Los Angeles, CA 90095, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,10,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"165rv13","DOI":"10.1126\/scitranslmed.3004404","article-title":"Hidden Killers: Human Fungal Infections","volume":"4","author":"Brown","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e383","DOI":"10.1016\/S1473-3099(17)30316-X","article-title":"The global problem of antifungal resistance: Prevalence, mechanisms, and management","volume":"17","author":"Perlin","year":"2017","journal-title":"Lancet Infect. Dis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.riam.2009.06.003","article-title":"Amphotericin B: Side effects and toxicity","volume":"26","year":"2009","journal-title":"Revista Iberoamericana de Micolog\u00eda"},{"key":"ref_4","unstructured":"Chiller, T. (2016, April 04). The Rise in Antifungal Resistance. Available online: https:\/\/www.medscape.com\/viewarticle\/861041#vp_1."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"6","DOI":"10.15585\/mmwr.mm6901a2","article-title":"Candida auris Isolates Resistant to Three Classes of Antifungal Medications\u2014New York, 2019","volume":"69","author":"Ostrowsky","year":"2020","journal-title":"MMWR. Morb. Mortal. Wkly. Rep."},{"key":"ref_6","first-page":"58","article-title":"Laboratory Analysis of an Outbreak of Candida auris in New York from 2016 to 2018: Impact and Lessons Learned","volume":"58","author":"Zhu","year":"2019","journal-title":"J. Clin. Microbiol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1055\/s-0035-1562894","article-title":"Emergence of Azole Resistance in Aspergillus","volume":"36","author":"Wiederhold","year":"2015","journal-title":"Semin. Respir. Crit. Care Med."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Liu, Y., Mittal, R., Solis, N.V., Prasadarao, N.V., and Filler, S.G. (2011). Mechanisms of Candida albicans Trafficking to the Brain. PLOS Pathog., 7.","DOI":"10.1371\/journal.ppat.1002305"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1097\/QCO.0000000000000111","article-title":"Echinocandin resistance","volume":"27","author":"Arendrup","year":"2014","journal-title":"Curr. Opin. Infect. Dis."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1093\/mmy\/myw060","article-title":"The anti-Aspergillus drug pipeline: Is the glass half full or empty?","volume":"55","author":"Osherov","year":"2017","journal-title":"Med. Mycol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1128\/CMR.00039-07","article-title":"Infections Caused by Scedosporium spp.","volume":"21","author":"Cortez","year":"2008","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1177\/2040620711410098","article-title":"Invasive fungal infections in acute leukemia","volume":"2","author":"Bhatt","year":"2011","journal-title":"Ther. Adv. Hematol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1080\/10428190310001653691","article-title":"Improved outcome of zygomycosis in patients with hematological diseases?","volume":"45","author":"Gleissner","year":"2004","journal-title":"Leuk. Lymphoma."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1086\/422729","article-title":"Zygomycosis: Reemergence of an old pathogen","volume":"39","author":"Kauffman","year":"2004","journal-title":"Clin. Infect. Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1128\/CMR.18.3.556-569.2005","article-title":"Novel Perspectives on Mucormycosis: Pathophysiology, Presentation, and Management","volume":"18","author":"Spellberg","year":"2005","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_16","unstructured":"Hata, K., Hori, T., Miyazaki, M., and Watanabe, N. (2011, January 17\u201320). In vitro and in vivo antifungal activities of E1211, a water-soluble prodrug of E1210, F1\u20131377. Proceedings of the Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, USA."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1046\/j.1365-2958.2003.03481.x","article-title":"Medicinal genetics approach towards identifying the molecular target of a novel inhibitor of fungal cell wall assembly","volume":"48","author":"Tsukahara","year":"2003","journal-title":"Mol. Microbiol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1021\/id5000212","article-title":"Chemical Genomics-Based Antifungal Drug Discovery: Targeting Glycosylphosphatidylinositol (GPI) Precursor Biosynthesis","volume":"1","author":"Mann","year":"2014","journal-title":"ACS Infect. Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"4624","DOI":"10.1016\/j.bmcl.2010.06.005","article-title":"Synthesis and evaluation of novel antifungal agents-quinoline and pyridine amide derivatives","volume":"20","author":"Nakamoto","year":"2010","journal-title":"Bioorganic Med. Chem. Lett."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"4652","DOI":"10.1128\/AAC.00291-11","article-title":"In VitroActivity of E1210, a Novel Antifungal, against Clinically Important Yeasts and Molds","volume":"55","author":"Miyazaki","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1128\/AAC.00731-11","article-title":"E1210, a New Broad-Spectrum Antifungal, Suppresses Candida albicans Hyphal Growth through Inhibition of Glycosylphosphatidylinositol Biosynthesis","volume":"56","author":"Watanabe","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1194\/jlr.R700002-JLR200","article-title":"Thematic review series: Lipid Posttranslational Modifications.GPI anchoring of protein in yeast and mammalian cells, or: How we learned to stop worrying and love glycophospholipids","volume":"48","author":"Orlean","year":"2007","journal-title":"J. Lipid Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"23639","DOI":"10.1074\/jbc.M301044200","article-title":"GWT1 Gene Is Required for Inositol Acylation of Glycosylphosphatidylinositol Anchors in Yeast","volume":"278","author":"Umemura","year":"2003","journal-title":"J. Biol. Chem."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"S475","DOI":"10.1093\/ofid\/ofx163.1218","article-title":"Fungal Cytological Profiling of Candida albicans Exposed to Diverse Antifungal Agents Including the Novel Gwt1 inhibitor APX001A","volume":"4","author":"Sharp","year":"2017","journal-title":"Open Forum Infect. Dis."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1021\/cb300235m","article-title":"Inhibiting GPI Anchor Biosynthesis in Fungi Stresses the Endoplasmic Reticulum and Enhances Immunogenicity","volume":"7","author":"McLellan","year":"2012","journal-title":"ACS Chem. Biol."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Covel, J.A., Soltow, Q.A., Kapoor, M., Moloney, M.K., Webb, P.J., Trzoss, M., Sharp, M., and Shaw, K.J. (2019). The Discovery of Manogepix\/Fosmanogepix and Other Gwt1 Inhibitors for the Treatment of Invasive Fungal Infections. Med. Chem. Rev., 221\u2013237.","DOI":"10.29200\/acsmedchemrev-v54.ch10"},{"key":"ref_27","unstructured":"Horii, T., Okubo, M., Miyazaki, M., Hata, K., and Watanabe, N.-A. (2010, January 12\u201315). In vivo pharmacodynamic correlates of success for E1210 treatment of disseminated candidiasis. F1\u2013843. Proceedings of the Interscience Conference on Antimicrobial Agents and Chemotherapy, Boston, MA, USA."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Huband, M.D., Pfaller, M.A., Flamm, R.K., Messer, S.A., Schaefer, B., Bien, P.A., and Castaneira, M. (2020, January 21\u201322). Activity of manogepix (APX001A) against 2669 fungal isolates from the SENTRY surveillance program (2018\u20132019) stratified by infection type. Proceedings of the IDWeek, Virtual Conference, Online.","DOI":"10.1093\/ofid\/ofaa439.1444"},{"key":"ref_29","first-page":"64","article-title":"In vitro Activity of Manogepix (APX001A) and Comparators against Contemporary Molds: MEC Comparison and Preliminary Experience with Colorimetric MIC Determination","volume":"64","author":"Astvad","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1128\/AAC.00840-19","article-title":"In vitro Activity of APX001A (Manogepix) and Comparator Agents against 1706 Fungal Isolates Collected during an International Surveillance Program in 2017","volume":"63","author":"Pfaller","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1093\/jac\/dkz022","article-title":"In vitro activity of APX001A against rare moulds using EUCAST and CLSI methodologies","volume":"74","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.diagmicrobio.2011.05.001","article-title":"In vitro activity of a novel broad-spectrum antifungal, E1210, tested against Candida spp. as determined by CLSI broth microdilution method","volume":"71","author":"Pfaller","year":"2011","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e02319-17","DOI":"10.1128\/AAC.02319-17","article-title":"In vitro and In Vivo Evaluation of the Antifungal Activity of APX001A\/APX001 against Candida auris","volume":"62","author":"Hager","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1128\/AAC.00429-20","article-title":"Manogepix (APX001A) Displays Potent In vitro Activity against Human Pathogenic Yeast, but with an Unexpected Correlation to Fluconazole MICs","volume":"64","author":"Arendrup","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Zhu, Y., Kilburn, S., Kapoor, M., Chaturvedi, S., Shaw, K.J., and Chaturvedi, V. (2020). Evaluation of in vitro activity of manogepix against multidrug-resistant and pan-resistant Candida auris from the New York Outbreak. Antimicrob. Agents Chemother.","DOI":"10.1101\/2020.06.02.129916"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1128\/AAC.05414-11","article-title":"Activities of E1210 and Comparator Agents Tested by CLSI and EUCAST Broth Microdilution Methods against Fusarium and Scedosporium Species Identified Using Molecular Methods","volume":"56","author":"Castanheira","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Arendrup, M., Chowdhary, A., J\u00f8rgensen, K.M., and Meletiadis, J. (2020). Manogepix (APX001A) in vitro activity against Candida auris. A head to head comparison of EUCAST and CLSI MICs. Antimicrob. Agents Chemother.","DOI":"10.1128\/AAC.00656-20"},{"key":"ref_38","unstructured":"CLSI (2017). Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts, Clinical and Laboratory Standards Institute. [4th ed.]. CLSI standard M27."},{"key":"ref_39","unstructured":"CLSI (2017). Reference Method for Broth Dilution Antifungal Susceptibility Testing of Filamentous Fungi, Clinical and Laboratory Standards Institute. [3rd ed.]. CLSI standard M38."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1128\/AAC.03944-14","article-title":"The Investigational Agent E1210 Is Effective in Treatment of Experimental Invasive Candidiasis Caused by Resistant Candida albicans","volume":"59","author":"Wiederhold","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"3060","DOI":"10.1093\/jac\/dky302","article-title":"Activity of novel antifungal compound APX001A against a large collection of Candida auris","volume":"73","author":"Berkow","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1128\/AAC.01387-19","article-title":"Evaluation of Resistance Development to the Gwt1 Inhibitor Manogepix (APX001A) in Candida Species","volume":"64","author":"Kapoor","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1128\/AAC.01120-19","article-title":"Efficacy of Delayed Therapy with Fosmanogepix (APX001) in a Murine Model of Candida auris Invasive Candidiasis","volume":"63","author":"Wiederhold","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"5155","DOI":"10.1128\/AAC.00570-11","article-title":"In vitro Activity of a Novel Broad-Spectrum Antifungal, E1210, Tested against Aspergillus spp. Determined by CLSI and EUCAST Broth Microdilution Methods","volume":"55","author":"Pfaller","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Badali, H., Patterson, H., Sanders, C., Mermella, B., Gibas, C., Mele, J., Fan, H., Ibrahim, A.S., Shaw, K.J., and Wiederhold, N.P. (2020, January 21\u201325). Manogepix, the active moiety of the investigational agent fosmanogepix, demonstrates in vitro activity against members of the Fusarium oxysporum and Fusarium solani species complexes. Proceedings of the IDweek 2020, Philadelphia, PA, USA. Poster 1282, IDSA: Online.","DOI":"10.1093\/ofid\/ofaa439.1465"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"S475","DOI":"10.1093\/ofid\/ofx163.1217","article-title":"APX001A Protects Immunosuppressed Mice from Rhizopus delemar Infection","volume":"4","author":"Gebremariam","year":"2017","journal-title":"Open Forum Infect. Dis."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"e01715-18","DOI":"10.1128\/AAC.01715-18","article-title":"APX001 and Other Gwt1 Inhibitor Prodrugs Are Effective in Experimental Coccidioides immitis Pneumonia","volume":"63","author":"Viriyakosol","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"6100","DOI":"10.1128\/AAC.00620-16","article-title":"Characterization of In vitro Resistance Development to the Novel Echinocandin CD101 in Candida Species","volume":"60","author":"Locke","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1128\/AAC.00261-20","article-title":"Enhanced Efflux Pump Expression in Candida Mutants Results in Decreased Manogepix Susceptibility","volume":"64","author":"Liston","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"AAC.01225-18","DOI":"10.1128\/AAC.01225-18","article-title":"APX001A In vitro Activity against Contemporary Blood Isolates and Candida auris Determined by the EUCAST Reference Method","volume":"62","author":"Arendrup","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"AAC.00425-18","DOI":"10.1128\/AAC.00425-18","article-title":"Significantly Improved Pharmacokinetics Enhances In Vivo Efficacy of APX001 against Echinocandin- and Multidrug-Resistant Candida Isolates in a Mouse Model of Invasive Candidiasis","volume":"62","author":"Zhao","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Ferrari, S., Sanguinetti, M., Torelli, R., Posteraro, B., and Sanglard, D. (2011). Contribution of CgPDR1-Regulated Genes in Enhanced Virulence of Azole-Resistant Candida glabrata. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0017589"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"4543","DOI":"10.1128\/AAC.00366-11","article-title":"Efficacy of Oral E1210, a New Broad-Spectrum Antifungal with a Novel Mechanism of Action, in Murine Models of Candidiasis, Aspergillosis, and Fusariosis","volume":"55","author":"Hata","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"e02542-17","DOI":"10.1128\/AAC.02542-17","article-title":"In Vivo Pharmacokinetics and Pharmacodynamics of APX001 against Candida spp. in a Neutropenic Disseminated Candidiasis Mouse Model","volume":"62","author":"Zhao","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_55","unstructured":"Petraitis, V., Petraitiene, R., Maung, B.B.W., Mansbach, R., Shaw, K.J., and Walsh, T.J. (2018, January 21\u201324). Efficacy of APX001 in treatment of Candida endophthalmitis and haematagenous meningoencephalitis in experimental non-neutropenic rabbit model. Proceedings of the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2018), Madrid, Spain."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"e00523-18","DOI":"10.1128\/AAC.00523-18","article-title":"In vitro and in vivo evaluation of APX001A\/APX001 and other Gwt1 inhibitors against Cryptococcus","volume":"62","author":"Shaw","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_57","unstructured":"Watanabe, N.-A., Horii, T., Miyazaki, M., and Hata, K. (2011, January 17). In vitro activity of E1210 and in vivo activity of E1211, a water-soluble prodrug of E1210, in combination with other antifungals. Proceedings of the F1\u20131378, in Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, USA."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1128\/AAC.02372-18","article-title":"APX001 Pharmacokinetic\/Pharmacodynamic Target Determination against Aspergillus fumigatus in an In Vivo Model of Invasive Pulmonary Aspergillosis","volume":"63","author":"Zhao","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"e01713-18","DOI":"10.1128\/AAC.01713-18","article-title":"APX001 Is Effective in the Treatment of Murine Invasive Pulmonary Aspergillosis","volume":"63","author":"Gebremariam","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1128\/AAC.01966-19","article-title":"Galactomannan Is a Biomarker of Fosmanogepix (APX001) Efficacy in Treating Experimental Invasive Pulmonary Aspergillosis","volume":"64","author":"Gebremariam","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_61","first-page":"64","article-title":"Fosmanogepix (APX001) Is Effective in the Treatment of Immunocompromised Mice Infected with Invasive Pulmonary Scedosporiosis or Disseminated Fusariosis","volume":"64","author":"Alkhazraji","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1128\/AAC.00178-20","article-title":"Fosmanogepix (APX001) Is Effective in the Treatment of Pulmonary Murine Mucormycosis Due to Rhizopus arrhizus","volume":"64","author":"Gebremariam","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Hodges, M.R., Ople, E., Shaw, K.J., Mansbach, R., Van Marle, S.P., Van Hoogdalem, E.-J., Kramer, W., and Wedel, P. (2017). Phase 1 Study to Assess Safety, Tolerability and Pharmacokinetics of Single and Multiple Oral Doses of APX001 and to Investigate the Effect of Food on APX001 Bioavailability. Open Forum Infect. Dis., 4.","DOI":"10.1093\/ofid\/ofx163.1390"},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Hodges, M.R., Ople, E., Shaw, K.J., Mansbach, R., Van Marle, S.J., Van Hoogdalem, E.-J., Wedel, P., and Kramer, W. (2017). First-in-Human Study to Assess Safety, Tolerability and Pharmacokinetics of APX001 Administered by Intravenous Infusion to Healthy Subjects. Open Forum Infect. Dis., 4.","DOI":"10.1093\/ofid\/ofx163.1370"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"e01157-17","DOI":"10.1128\/mBio.01157-17","article-title":"Pharmacodynamics of the Orotomides against Aspergillus fumigatus: New Opportunities for Treatment of Multidrug-Resistant Fungal Disease","volume":"8","author":"Hope","year":"2017","journal-title":"mBio"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"661","DOI":"10.3389\/fmicb.2018.00661","article-title":"Galactomannan, a Surrogate Marker for Outcome in Invasive Aspergillosis: Finally Coming of Age","volume":"9","author":"Mercier","year":"2018","journal-title":"Front. Microbiol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"S472","DOI":"10.1093\/ofid\/ofx163.1209","article-title":"Absorption, Distribution, and Excretion of 14C-APX001 after Single-Dose Administration to Rats and Monkeys","volume":"4","author":"Mansbach","year":"2017","journal-title":"Open Forum Infect. Dis."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1093\/cid\/ciy827","article-title":"Isavuconazole Versus Caspofungin in the Treatment of Candidemia and Other Invasive Candida Infections: The ACTIVE Trial","volume":"68","author":"Kullberg","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"ref_69","unstructured":"Amplyx website (2020, July 20). Amplyx Announces Positive Top-Line Data in Phase 2 Clinical Trial of Novel Antifungal Fosmanogepix. Available online: https:\/\/amplyx.com\/amplyx-announces-positive-top-line-data-in-phase-2-clinical-trial-of-novel-antifungal-fosmanogepix\/."},{"key":"ref_70","unstructured":"Amplyx website (2019, September 09). FDA Grants Fast Track Status to Amplyx Pharmaceuticals for IV and Oral Formulation of Fosmanogepix (APX001) for Seven Different Indications. Available online: https:\/\/amplyx.com\/fda-grants-fast-track-status-to-amplyx-pharmaceuticals-for-iv-and-oral-formulations-of-fosmanogepix-apx001-for-seven-different-indications\/."}],"container-title":["Journal of Fungi"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2309-608X\/6\/4\/239\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:26:01Z","timestamp":1760178361000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2309-608X\/6\/4\/239"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,22]]},"references-count":70,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["jof6040239"],"URL":"https:\/\/doi.org\/10.3390\/jof6040239","relation":{},"ISSN":["2309-608X"],"issn-type":[{"value":"2309-608X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,22]]}}}